Natriuretic peptides in heart failure: should therapy be guided by BNP levels?

Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Testing for natriuretic peptide markers, such as B-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP), has emerged as an important tool for the diagnosis and risk stratification of patients with HF. However, questions remain regarding the potential role for natriuretic peptides to guide therapy in patients with HF. In this Review, we address the underlying assumptions and the existing evidence supporting a natriuretic-peptide-guided approach to the outpatient management of HF.

[1]  Naoto Minamino,et al.  A new natriuretic peptide in porcine brain , 1988, Nature.

[2]  Michael L. Johnson,et al.  Deconvolution Analysis of Cardiac Natriuretic Peptides During Acute Volume Overload , 2000, Hypertension.

[3]  Moĭbenko Aa,et al.  The heart as an endocrine organ , 1990 .

[4]  O. Vuolteenaho,et al.  B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. , 1998, Annals of medicine.

[5]  R. Doughty,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 2001, Journal of the American College of Cardiology.

[6]  J. Cohn,et al.  Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT) , 2002, Circulation.

[7]  S. Réhman,et al.  Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[8]  A. Dobson,et al.  How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review , 2005, BMJ : British Medical Journal.

[9]  D. Levy,et al.  Impact of age and sex on plasma natriuretic peptide levels in healthy adults. , 2002, The American journal of cardiology.

[10]  Robert H Christenson,et al.  National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. , 2007, Circulation.

[11]  Faquan Liang,et al.  Evidence for functional heterogeneity of circulating B-type natriuretic peptide. , 2007, Journal of the American College of Cardiology.

[12]  C. Frampton,et al.  Abstract 5946: Ntprobnp Guided Treatment for Chronic Heart Failure: Results from the Battlescarred Trial , 2008 .

[13]  E. Hartter,et al.  Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[14]  Gabriel Thabut,et al.  Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. , 2004, Journal of the American College of Cardiology.

[15]  A. Ferreira,et al.  N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.

[16]  D. Lloyd‐Jones,et al.  Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. , 2006, Journal of the American College of Cardiology.

[17]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[18]  C. Yancy,et al.  Influence of hospital length of stay for heart failure on quality of care. , 2008, The American journal of cardiology.

[19]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[20]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[21]  M. Emi,et al.  Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels. , 2007, Biochemical and biophysical research communications.

[22]  D. Levy,et al.  Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.

[23]  H. S. Kim,et al.  Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Struthers,et al.  Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction , 1993, The Lancet.

[25]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[26]  N. Freemantle,et al.  Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial. , 2008, Journal of the American College of Cardiology.

[27]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[28]  J. P. Henry,et al.  Evidence of the Atrial Location of Receptors Influencing Urine Flow , 1956, Circulation research.

[29]  D. Levy,et al.  Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure , 2009, Nature Genetics.

[30]  M. McCarthy,et al.  Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. , 2007, Human molecular genetics.

[31]  Harlan M Krumholz,et al.  ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society , 2005, Circulation.

[32]  A. Cohen-Solal,et al.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.

[33]  R. Califf,et al.  Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. , 2005, American heart journal.

[34]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[35]  J. Rouleau,et al.  Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial , 2004, Circulation.

[36]  M. Cheitlin,et al.  BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial , 2010 .

[37]  Kenji Nakamura,et al.  Cardiac fibrosis in mice lacking brain natriuretic peptide. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. Yancy,et al.  Use of aldosterone antagonists in heart failure. , 2009, JAMA.

[39]  R. White,et al.  Letter by Tang et al regarding article, "BIPHASIC trial: a randomized comparison of fixed lower versus escalating higher energy levels for defibrillation in out-of-hospital cardiac arrest". , 2007, Circulation.

[40]  M. Pfeffer,et al.  Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. , 2007, Journal of the American College of Cardiology.

[41]  G. Palade,et al.  SPECIFIC GRANULES IN ATRIAL MUSCLE CELLS , 1964, The Journal of cell biology.

[42]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.

[43]  R. Doughty,et al.  Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 1999, Circulation.

[44]  J. Cohn,et al.  Valsartan in heart failure trial (Val-HeFT) , 1998 .

[45]  C. Frampton,et al.  Introduction of Metoprolol Increases Plasma B-Type Cardiac Natriuretic Peptides in Mild, Stable Heart Failure , 2006, Circulation.

[46]  A. Richards,et al.  Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. , 1993, British heart journal.

[47]  M. Kinoshita,et al.  Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[48]  P. Twomey,et al.  Using the single-compartment ratio model to calculate half-life, NT-proBNP as an example. , 2007, Clinica chimica acta; international journal of clinical chemistry.